アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - sodium cation 1.102 g - osmoprep tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. osmoprep tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy. osmoprep tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. laxatives and purgatives (including osmoprep) have the potential for abuse by bulimia nervosa patients who frequently have binge eating and vomiting.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)] - severe renal impairment (egfr less than 30 ml/min/1.73m2 ) or end stage renal disease [see warning and precautions (5.3)] - hyperphosphatemia [see warning and precautions (5.4)] - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates inj

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in the following conditions: -   history of acute phosphate nephropathy [see warnings and precautions (5.1)] -   gastrointestinal (gi) obstruction [see warnings and precautions (5.7)] -   gastric bypass or stapling surgery -   bowel perforation -   toxic colitis -   toxic megacolon -   hypersensitivity to sodium phosphate salts or any component of monobasic sodium phosphate and dibasic sodium phosphate tablets[see warnings and precautions (5.7)]. risk summary there are no available data on sodium phosphate use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with sodium phosphate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of sodium phosphate in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of monobasic sodium phosphate and dibasic sodium phosphate tablets to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for monobasic sodium phosphate and dibasic sodium phosphate tablets and any potential adverse effects on the breastfed child from monobasic sodium phosphate and dibasic sodium phosphate tablets or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. of the 599 patients in clinical trials receiving at least 48 grams of monobasic sodium phosphate and dibasic sodium phosphate tablets, 134 (22%) were 65 years of age or older, while 27 (5%) were 75 years of age or older. no overall differences in safety or effectiveness were observed between geriatric patients and younger patients. however, the mean phosphate levels in geriatric patients were greater than the phosphate levels in younger patients after monobasic sodium phosphate and dibasic sodium phosphate tablets administration. the mean colonoscopy-day phosphate levels in patients 18-64, 65-74, and ≥ 75 years old who received the recommended monobasic sodium phosphate and dibasic sodium phosphate tablets dosage regimen in study 1were 7.0, 7.3, and 8.0 mg/dl, respectively. after monobasic sodium phosphate and dibasic sodium phosphate tablets administration, the mean phosphate levels in patients 18-64, 65-74, and ≥ 75 years old were 7.4, 7.9, and 8.0 mg/dl, respectively. greater sensitivity of some older individuals cannot be ruled out; therefore, use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in geriatric patients. advise geriatric patients to adequately hydrate before, during, and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets. sodium phosphate is known to be substantially excreted by the kidney, and the risk of adverse reactions with sodium phosphate may be greater in patients with impaired renal function. since geriatric patients are more likely to have impaired renal function, consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1)]. sodium phosphate is substantially excreted by the kidney. use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in patients with severe renal impairment (creatinine clearance less than 30 ml/min) or patients taking concomitant medications that may affect renal function. these patients may be at risk for renal injury. advise these patients of the importance of adequate hydration before, during and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets, and consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1), drug interactions (7.1)] .

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

amneal pharmaceuticals private limited - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)]. - hyperphosphatemia [see warning and precautions (5.4)]. - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] .  - severe renal impairment (egfr less than 30 ml/min/1.73 m2 ) or end stage renal disease [see warning and precautions (5.3)] . risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk phosphorus is an essential mineral element. parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake. risk summary phosphorus and potassium are present in human milk. administration of the recommended dose of potassium phosphates injection is not expected to cause harm to a breastfed infant. there is no information on the effects of potassium phosphates on milk production. the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for potassium phosphates injection and any potential adverse effects on the breastfed child from potassium phosphates injection or from underlying maternal condition. safety and effectiveness of potassium phosphates injection have been established in pediatric patients as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. - for parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated. because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.6)] . in general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. it may be useful to monitor renal function during treatment [see use in specific populations (8.6)] . potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function [see warnings and precautions (5.3, 5.4, 5.5)] . potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (egfr less than 30 ml/min/1.73 m2 ) or end stage renal disease [see contraindications (4)] . in patients with moderate renal impairment (egfr ≥ 30 ml/min/1.73 m2 to < 60 ml/min/1.73 m2 ), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium and magnesium concentrations [see dosage and administration (2.2, 2.4)].

カナダ - 英語 - Health Canada

biocentre - magnesium phosphate dibasic; calcium phosphate (tribasic); ferric phosphate; potassium chloride; potassium phosphate dibasic; potassium sulfate; sodium chloride; sodium phosphate dibasic; silicon dioxide - tablet - 12x; 6x; 6x; 6x; 6x; 6x; 12x; 12x; 6x - magnesium phosphate dibasic 12x; calcium phosphate (tribasic) 6x; ferric phosphate 6x; potassium chloride 6x; potassium phosphate dibasic 6x; potassium sulfate 6x; sodium chloride 12x; sodium phosphate dibasic 12x; silicon dioxide 6x - homeopathic products

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hyland's inc. - sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr), tribasic calcium phosphate (unii: 91d9gv0z28) (phosphate ion - unii:nk08v8k8hr), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr), magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838) - natural relief of anxiousness, nervousness and irritability ■ helps temporarily relieves symptoms of: ■ restlessness ■ anxiousness ■ nervousness ■ irritability ■ apprehensiveness

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hyland's inc. - silicon dioxide (unii: etj7z6xbu4) (silicon dioxide - unii:etj7z6xbu4), tribasic calcium phosphate (unii: 91d9gv0z28) (phosphate ion - unii:nk08v8k8hr), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838), sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - ■ temporarily relieves: ■ cold symptoms ■ nervous tension ■ fatigue ■ headaches cold symptoms nervous tension fatigue headaches

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

homeocare laboratories - arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), copper (unii: 789u1901c5) (copper - unii:789u1901c5), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr), lactic acid, dl- (unii: 3b8d35y7s4) (lactic acid, dl- - unii:3b8d35y7s4), magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838) - arnica montana 18 [hp_x] in 4 g - temporarily relieves minor aches and pains associated with backache, strains, sprains, bruises, and sports injuries. turn tube upside down, twist cap to break seal & release pellets. using clear cap, place 3 pellets to dissolve under your tongue 3 times a day or as needed. take apart from food or drinks. to preserve purity avoid touching pellets with fingers.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hyland's - calcium phosphate (unii: 97z1wi3ndx) (calcium cation - unii:2m83c4r6zb), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), potassium phosphate, unspecified form (unii: b7862wz632) (potassium phosphate, unspecified form - unii:b7862wz632), magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838), sodium phosphate (unii: se337svy37) (phosphate ion - unii:nk08v8k8hr) - temporarily relieves the symptoms of stress, nervousness, mental anxiousness, irritability, and the inability to concentrate.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

trp company - euphrasia stricta (unii: c9642i91wl) (euphrasia stricta - unii:c9642i91wl), pilocarpus jaborandii whole (unii: 7y2u36db42) (pilocarpus jaborandii whole - unii:7y2u36db42), copper (unii: 789u1901c5) (copper - unii:789u1901c5), amanita muscaria fruiting body (unii: dif093i037) (amanita muscaria fruiting body - unii:dif093i037), magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838), physostigma venenosum seed (unii: cjv9e9iioa) (physostigma venenosum seed - unii: - agaricus muscarius hpu......spasms cuprum metallicum hpus......twitching lids euphrasia hpus..............dryness, irritation jaborandi hpus..............eyestrain, fatigue magnesia phosphorica hpus...twitching under eye physostigma venenosum hpus..nervous tension stannum metallicum hpus.....eye twitching uses:* according to homeopathic indications these ingredients provide temporary relief from symptoms such as: • eye spasms • sensitivity to light • irritation • eye quivering • eyestrain • twitching lids • tired eyes; after serious causes have been ruled out by a physician. *these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. - if solution changes color or becomes cloudy. - if you frequently contract infections that do not clear up easily. - if you experience eye pain or changes in vision. - if you are experiencing a thick, white, yellow, or green discharge that forms a crust on the eyelid. -